gilteritinib   Click here for help

GtoPdb Ligand ID: 8708

Synonyms: ASP-2215 | ASP2215 | Xospata®
Approved drug PDB Ligand
gilteritinib is an approved drug (FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3), AXL and anaplastic lymphoma kinase (ALK) [4], with clinical antineoplastic activity. Gilteritinib inhibits the activity of FLT3-activating mutations which are one of the most common genetic alterations in acute myeloid leukemia (AML).

SARS-CoV-2: AXL is a kinase upstream of p38 MAP kinases. p38 activity has been reported to be upregulated following SARS-CoV-2 infection of host cells in vitro, and gilteritinib produces an antiviral effect (IC50= 807 nM) [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 121.11
Molecular weight 552.35
XLogP 2.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC
Isomeric SMILES COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC
InChI InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
InChI Key GYQYAJJFPNQOOW-UHFFFAOYSA-N
Bioactivity Comments
The compound may be used as gilteritinib fumarate (PubChem CID 76970819).
In preclinical in vitro studies using leukemia cells expressing wild type (WT) or mutated FLT3, gilteritinib was a potent inhibitor of proliferation in all cell lines [4]. For example, the IC50 vs. cells with WT FLT3 was 5 nM, and in FLT3-ITD mutant cells and cells with FLT3 point mutations it was <2 nM. The IC50 against cells with the F691L gatekeeper mutation was marginally higher at ~12 nM.
The IC50 values in the table below are estimates from the graph provided in Supplemental Figure 1 in the article that reports preclinical evaluation of gilteritinib activity, by Lee et al. (2017) [4]. These values were determined using a DiscoverX® kinase selectivity screening assay.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
leukocyte receptor tyrosine kinase Hs Inhibitor Inhibition ~9.7 pIC50 - 4
⤷ pIC50 ~9.7 (IC50 ~2x10-10 M) [4]
fms related receptor tyrosine kinase 3 Hs Inhibitor Inhibition ~9.5 pIC50 - 4
⤷ pIC50 ~9.5 (IC50 ~3x10-10 M) [4]
ALK receptor tyrosine kinase Hs Inhibitor Inhibition ~9.3 pIC50 - 4
⤷ pIC50 ~9.3 (IC50 ~5x10-10 M) [4]
AXL receptor tyrosine kinase Hs Inhibitor Inhibition ~9.1 pIC50 - 4
⤷ pIC50 ~9.1 (IC50 ~8x10-10 M) [4]
neurotrophic receptor tyrosine kinase 1 Hs Inhibitor Inhibition ~9.0 pIC50 - 4
⤷ pIC50 ~9.0 (IC50 ~1.1x10-9 M) [4]
c-ros oncogene 1, receptor tyrosine kinase Hs Inhibitor Inhibition ~8.8 pIC50 - 4
⤷ pIC50 ~8.8 (IC50 ~1.5x10-9 M) [4]
ret proto-oncogene Hs Inhibitor Inhibition ~8.8 pIC50 - 4
⤷ pIC50 ~8.8 (IC50 ~1.7x10-9 M) [4]
MER proto-oncogene, tyrosine kinase Hs Inhibitor Inhibition ~8.5 pIC50 - 4
⤷ pIC50 ~8.5 (IC50 ~3x10-9 M) [4]